FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334974730> ?p ?o ?g. }

• W2334974730 endingPage "260" @default.
• W2334974730 startingPage "255" @default.
• W2334974730 abstract "Background Despite the efficacy of gemcitabine-platinum regimen, the outcome of patients with recurrent and/or metastatic nasopharyngeal carcinoma (RM NPC) is poor. A phase II trial was conducted to determine the efficacy of erlotinib, given as maintenance therapy after gemcitabine-platinum chemotherapy in patients with RM NPC. Patients and Methods Patients were treated with gemcitabine 1000 mg/m2 on days 1 and 8 as well as cisplatin 70 mg/m2 on day 1 (or carboplatin area under curve 5 on day 1, if contraindication to cisplatin) 3 weeks. After 6 chemotherapy cycles (or before in case of progression), patients were switched to erlotinib 150 mg/d 4 weeks. Primary end point was time to progression in patients without progressive disease after 6 chemotherapy cycles and treated with maintenance erlotinib. Epstein-Barr virus DNA plasma levels, measured using quantitative real-time polymerase chain reaction, were correlated with outcome. Results Of 20 enrolled patients, 19 patients received 96 chemotherapy cycles. Fifteen patients were switched to erlotinib and received 36 cycles (range: 1 to 6 cycles). Safety profiles observed with the chemotherapy combination and erlotinib were those expected. Of 12 patients evaluable for response to erlotinib, all progressed except 3 patients (25%) who had stable disease for 3, 4, and 7 months, respectively. Median time to progression was 6.9 months for 13 patients without progressive disease after 6 chemotherapy cycles and treated with erlotinib. No correlation was identified between Epstein-Barr virus DNA plasma levels and clinical outcome. Conclusions Maintenance or second-line therapy with erlotinib after chemotherapy was not effective in RM NPC. Historical comparison with patients treated with the same chemotherapy alone until progression suggests that it may be detrimental to stop chemotherapy after 6 cycles if disease did not progress." @default.
• W2334974730 created "2016-06-24" @default.
• W2334974730 creator A5000204204 @default.
• W2334974730 creator A5018195674 @default.
• W2334974730 creator A5020206972 @default.
• W2334974730 creator A5028677586 @default.
• W2334974730 creator A5040373320 @default.
• W2334974730 creator A5047227744 @default.
• W2334974730 creator A5063649167 @default.
• W2334974730 creator A5067772666 @default.
• W2334974730 creator A5073787373 @default.
• W2334974730 creator A5086730784 @default.
• W2334974730 date "2012-06-01" @default.
• W2334974730 modified "2023-09-30" @default.
• W2334974730 title "A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma" @default.
• W2334974730 cites W1565302522 @default.
• W2334974730 cites W1968017437 @default.
• W2334974730 cites W1977966489 @default.
• W2334974730 cites W1996085400 @default.
• W2334974730 cites W2017445928 @default.
• W2334974730 cites W2040471871 @default.
• W2334974730 cites W2043696829 @default.
• W2334974730 cites W2061468014 @default.
• W2334974730 cites W2086931150 @default.
• W2334974730 cites W2086978035 @default.
• W2334974730 cites W2095617994 @default.
• W2334974730 cites W2095618958 @default.
• W2334974730 cites W2104514175 @default.
• W2334974730 cites W2110614795 @default.
• W2334974730 cites W2116631159 @default.
• W2334974730 cites W2121179939 @default.
• W2334974730 cites W2125919881 @default.
• W2334974730 cites W2131928389 @default.
• W2334974730 cites W2138297714 @default.
• W2334974730 cites W2139248078 @default.
• W2334974730 cites W2152755651 @default.
• W2334974730 cites W2152816062 @default.
• W2334974730 cites W2153972462 @default.
• W2334974730 cites W2158134441 @default.
• W2334974730 cites W2161821474 @default.
• W2334974730 cites W2162724777 @default.
• W2334974730 cites W2328395336 @default.
• W2334974730 doi "https://doi.org/10.1097/coc.0b013e31820dbdcc" @default.
• W2334974730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21358293" @default.
• W2334974730 hasPublicationYear "2012" @default.
• W2334974730 type Work @default.
• W2334974730 sameAs 2334974730 @default.
• W2334974730 citedByCount "40" @default.
• W2334974730 countsByYear W23349747302012 @default.
• W2334974730 countsByYear W23349747302013 @default.
• W2334974730 countsByYear W23349747302014 @default.
• W2334974730 countsByYear W23349747302016 @default.
• W2334974730 countsByYear W23349747302017 @default.
• W2334974730 countsByYear W23349747302018 @default.
• W2334974730 countsByYear W23349747302019 @default.
• W2334974730 countsByYear W23349747302020 @default.
• W2334974730 countsByYear W23349747302021 @default.
• W2334974730 countsByYear W23349747302022 @default.
• W2334974730 countsByYear W23349747302023 @default.
• W2334974730 crossrefType "journal-article" @default.
• W2334974730 hasAuthorship W2334974730A5000204204 @default.
• W2334974730 hasAuthorship W2334974730A5018195674 @default.
• W2334974730 hasAuthorship W2334974730A5020206972 @default.
• W2334974730 hasAuthorship W2334974730A5028677586 @default.
• W2334974730 hasAuthorship W2334974730A5040373320 @default.
• W2334974730 hasAuthorship W2334974730A5047227744 @default.
• W2334974730 hasAuthorship W2334974730A5063649167 @default.
• W2334974730 hasAuthorship W2334974730A5067772666 @default.
• W2334974730 hasAuthorship W2334974730A5073787373 @default.
• W2334974730 hasAuthorship W2334974730A5086730784 @default.
• W2334974730 hasConcept C121608353 @default.
• W2334974730 hasConcept C126322002 @default.
• W2334974730 hasConcept C143998085 @default.
• W2334974730 hasConcept C2776694085 @default.
• W2334974730 hasConcept C2778087573 @default.
• W2334974730 hasConcept C2778239845 @default.
• W2334974730 hasConcept C2778822529 @default.
• W2334974730 hasConcept C2778997737 @default.
• W2334974730 hasConcept C2779438470 @default.
• W2334974730 hasConcept C2780258809 @default.
• W2334974730 hasConcept C2781413609 @default.
• W2334974730 hasConcept C2781451048 @default.
• W2334974730 hasConcept C2909325608 @default.
• W2334974730 hasConcept C509974204 @default.
• W2334974730 hasConcept C71924100 @default.
• W2334974730 hasConcept C90924648 @default.
• W2334974730 hasConceptScore W2334974730C121608353 @default.
• W2334974730 hasConceptScore W2334974730C126322002 @default.
• W2334974730 hasConceptScore W2334974730C143998085 @default.
• W2334974730 hasConceptScore W2334974730C2776694085 @default.
• W2334974730 hasConceptScore W2334974730C2778087573 @default.
• W2334974730 hasConceptScore W2334974730C2778239845 @default.
• W2334974730 hasConceptScore W2334974730C2778822529 @default.
• W2334974730 hasConceptScore W2334974730C2778997737 @default.
• W2334974730 hasConceptScore W2334974730C2779438470 @default.
• W2334974730 hasConceptScore W2334974730C2780258809 @default.
• W2334974730 hasConceptScore W2334974730C2781413609 @default.
• W2334974730 hasConceptScore W2334974730C2781451048 @default.

• next